Oscient files for chapter 11 protection and sells Factive
This article was originally published in Scrip
Executive Summary
Oscient Pharmaceuticals and its wholly owned subsidiary Guardian II Acquisition have both filed for Chapter 11 bankruptcy protection in the US, and Oscient is selling its antibiotic Factive (gemifloxacin mesylate) to Cornerstone Therapeutics.